Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/29994
Başlık: A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer
Yazarlar: Tsimplouli, Chrisiida
Sereti, Evangelia
Dimas, Konstantinos
Ilkay Armutak, Elif
Gurevin, Ebru Gurel
Üvez, Ayça
Mori, Mattia
Berardozzi, Simone
Ingallina, Cinzia
D'Acquarica, Ilaria
Botta, Bruno
Özpolat, Bülent
Ulukaya, Engin
Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü.
0000-0002-3127-742X
0000-0003-3118-8061
0000-0002-3781-6834
0000-0001-9631-3551
Cevatemre, Buse
Erkısa, Merve
Aztopal, Nazlıhan
Karakaş, Didem
Alper, Pınar
AHD-2050-2022
AAM-1001-2020
L-6687-2018
L-6682-2018
55693788600
57126208900
55853882900
56422040600
57197858774
Anahtar kelimeler: Triterpenoid
Mammosphere
Endoplasmic reticulum stress
Cytoplasmic vacuolation
Signaling pathway
Autophagy
Degradation
Carcinoma
Proliferation
Palladium(ıı)
Doxorubicin
Triterpenes
Metastasis
Yayın Tarihi: 2-Ara-2017
Yayıncı: Academic Press
Atıf: Cevatemre, B. vd. (2018). ''A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer''. Pharmacological Research, 129, 500-514.
Özet: Several natural products have been suggested as effective agents for the treatment of cancer. Given the important role of CSCs (Cancer Stem Cells) in cancer, which is a trendy hypothesis, it is worth investigating the effects of pristimerin on CSCs as well as on the other malignant cells (MCF-7 and MDA-MB-231) of breast cancer. The anti-growth activity of pristimerin against MCF-7 and MCF-7s (cancer stem cell enriched population) cells was investigated by real time viability monitorization (xCELLigence System (R)) and ATP assay, respectively. Mode of cell death was evaluated using electron and fluorescence microscopies, western blotting (autophagy, apoptosis and ER-stress related markers) and flow cytometry (annexin-V staining, caspase 3/7 activity, BCL-2 and PI3K expressions). Pristimerin showed an anti-growth effect on cancer cells and cancer stem cells with IC50 values ranging at 0.38-1.75 mu M. It inhibited sphere formation at relatively lower doses (<1.56 mu M). Apoptosis was induced in MCF-7 and MCF-7s cells. In addition, extensive cytoplasmic vacuolation was observed, implying an incompleted autophagy as evidenced by the increase of autophagy-related proteins (p62 and LC3-II) with an unfolded protein response (UPR). Pristimerin inhibited the growth of MCF-7 and MDA-MB-231-originated xenografts in NOD.CB17-Prkdc(scid)/J mice. In mice, apoptosis was further confirmed by cleavage of PARP, activation of caspase 3 and/or 7 and TUNEL staining. Taken together, pristimerin shows cytotoxic activity on breast cancer both in vitro and in vivo. It seems to represent a robust promising agent for the treatment of breast cancer. Pristimerin's itself or synthetic novel derivatives should be taken into consideration for novel potent anticancer agent(s).
URI: https://doi.org/10.1016/j.phrs.2017.11.027
https://www.sciencedirect.com/science/article/pii/S1043661817309933
http://hdl.handle.net/11452/29994
ISSN: 1043-6618
Koleksiyonlarda Görünür:PubMed
Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.